|
|
|
|
|
What to Expect from the 2025 American Urological Association Annual Meeting
|
|
|
|
|
| Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting |
| Press Release |
| At AUA 2025, Bayer will present new data highlighting NUBEQA® (darolutamide) across multiple stages of prostate cancer, including ultra-low PSA response data from the ARANOTE trial and a focused analysis on Black patients. Additional presentations will cover long-term safety from the ARASENS Rollover trial, real-world findings from the DAROL study, and insights into caregiver challenges from a U.S.-based survey. |
|
|
|
|
|
| UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers |
| Press Release
|
| UroGen will present new data supporting its urothelial cancer portfolio, including 18-month duration of response data for UGN-102 and patient-reported outcomes from multiple trials in low-grade intermediate-risk NMIBC. Additional presentations will cover long-term outcomes from the OPTIMA II study, follow-up results from the JELMYTO OLYMPUS trial, and Phase 1 data on UGN-301, an anti-CTLA-4 antibody in development. |
|
|
|
|
|
|
|
|
|
| IP02: Bladder Cancer: Non-Invasive I - 7:00 AM - 9:00 AM
|
|
|
|
|
|
|
The Computational Histology Artificial Intelligence (CHAI) Biomarker Enhances Risk Stratification of High-Grade Ta Non-Muscle Invasive Bladder Cancer in a Multicenter Cohort: Comparison to 2024 AUA Guidelines
Presented By: Sam Chang, MD, MBA
|
|
|
|
|
Phase III, Single-Arm Study to Evaluate the Efficacy and Safety of Intravesical Paclitaxel-Hyaluronic Acid Conjugate in Patients with BCG-Unresponsive Carcinoma in Situ of the Bladder +/- Ta-T1 Papillary Disease (Orion-BC Study)
Presented By: Max Kates, MD
|
|
|
|
|
Performance of the EORTC and CUETO Risk Prediction Models in Contemporary Patients Undergoing Transurethral Resection of Bladder Tumor with Blue Light Cystoscopy
Presented By: Agustin Perez-Londono, MD
|
|
|
|
|
|
|
PD01: Stone Disease: Surgical Therapy (including ESWL) I - 7:00 AM - 9:00 AM |
|
|
|
|
|
|
The Effect of High-Power Lasers on Renal Temperature During Intrarenal Surgery
Presented By: Kavita Gupta, MD
|
|
|
|
|
|
|
| Plenary - 7:30 AM - 11:30 AM
|
|
|
|
|
|
|
Sasanlimab in Combination with Bacillus Calmette-Guerin Improves Event-Free Survival Versus Bacillus Calmette-Guerin as Standard of Care in High-Risk Non-Muscle-Invasive Bladder Cancer
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ
Presented By: Mark Tyson, II, MD, MPH
TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin–unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Carcinoma in Situ: 1-Year Durability and Patient-Reported Outcome
Presented By: Joseph Jacob, MD
TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin–unresponsive Papillary Disease–only High-Risk Non–muscle-Invasive Bladder Cancer: First Results from Cohort 4 of SunRISe-1
Presented By: Félix Guerrero Ramos MD, PhD, FEBU
|
|
|
|
|
|
|
|
|
|
|
|
| MP08: Bladder Cancer: Epidemiology & Evaluation I - 1:00 PM - 3:00 PM
|
|
|
|
|
|
|
Clinical Utility of a Urinary Biomarker (CxBladder Triage) Compared to Standard of Care for Microscopic Hematuria Evaluations in a Large Independent Delivery Network.
Presented By: Christopher Filson, MD
|
|
|
|
|
|
|
| PD12: Bladder Cancer: Non-Invasive II - 3:30 PM - 5:30 PM
|
|
|
|
|
|
|
An Update on QUILT-3.032: Complete Responses to N-803 plus BCG Therapy in BCG-Unresponsive Bladder Carcinoma In Situ (CIS) With or Without Ta/T1 Papillary Disease
Presented By: Sam Chang, MD, MBA
|
|
|
|
|
|
|
|
|
| PD13: Prostate Cancer: Advanced (Including Drug Therapy) I - 9:30 AM - 11:30 AM
|
|
|
|
|
|
|
BMS-986365 (CC-94676), a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from Additional Exploratory Analyses
Presented By: Manish Patel, MD
|
|
|
|
|
PSMA-Targeted Actinium-225 Therapy in Metastatic Castration-Resistant Prostate Cancer: Comparative Outcomes Between Monotherapy vs. Combination Therapy
Presented By: Valentina Marulanda Corzo, MD
|
|
|
|
|
|
|
| MP13: Prostate Cancer: Staging - 09:30 AM - 11:30 AM |
|
|
|
|
|
|
COBRA: Assessment of 64Cu-SAR-bisPSMA and Standard of Care Prostate-Specific Membrane Antigen Positron Emission Tomography in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
|
|
| MP14: Kidney Cancer: Advanced (including Drug Therapy) I - 9:30 AM - 11:30 AM |
|
|
|
|
|
|
Upfront Cytoreductive Nephrectomy with Deferred Systemic Therapy for Metastatic Renal Cell Carcinoma
Presented By: Bimal Bhindi, MD
|
|
|
|
|
|
|
| Plenary - 7:30 AM - 11:40 AM
|
|
|
|
|
|
|
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Randomized Multicenter Trial of Ureteral Stent Placement Versus Stent Omission After Ureteroscopy for Renal Stones
Presented By: Seth Bechis, MD, MS
|
|
|
|
|
|
|
| MP16: Prostate Cancer: Advanced (Including Drug Therapy) II - 1:00 PM - 3:00 PM
|
|
|
|
|
|
|
Efficacy and Safety of Darolutamide Plus Androgen-Deprivation Therapy (ADT) in Black Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the Phase 3 ARANOTE Trial
Presented By: Quoc-Dien Trinh, MD, MBA
|
|
|
|
|
|
|
|
|
| PD26: Kidney Cancer: Epidemiology & Evaluation/Staging/Surveillance II - 9:30 AM - 11:30 AM |
|
|
|
|
|
|
Renal Mass Biopsy for Small Renal Masses: A Single-Center 20-Year Experience
Presented By: Lucshman Raveendran, MD, MSc
|
|
|
|
|
|
|
AUA – IBCG Bladder Cancer Forum -Common Problems and Controversies in Bladder Cancer -
Ashish Kamat, MD, MBBS, FACS, and Kelly Bree, MD - 2:00 PM - 5:00 PM
|
|
|
|
|
|
|
|
|
| Engineering in Urology Society at the AUA POSTER SESSION 2 - 2:30 PM – 3:30 PM
|
|
|
|
|
|
|
EUS: Improved Control of Renal Pelvis Pressure Using a Prototype Fluid Management System Incorporating Ureteroscope Pressure Feedback
Presented By: Leilane Glienke, MD
|
|
|
|
|
|
|
|
|
| PD36: Kidney Cancer: Localized: Surgical Therapy IV - 7:00 AM - 9:00 AM
|
|
|
|
|
|
|
Robotic-assisted partial nephrectomy in augmented reality: reliability of a neural network training methodology for automated renal parenchyma recognition (UroCCR 112)
Presented By: Alice Pitout, MD
|
|
|
|
|
|
|
| IP26: Prostate Cancer: Advanced (Including Drug Therapy) III - 9:30 AM - 11:30 AM
|
|
|
|
|
|
|
Long-Term Safety and Tolerability of Extended Treatment with Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Insights from ARASENS Rollover Study
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
Ultra-Low PSA Response (<0.02 ng/mL) with Darolutamide plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 PSMAfore Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
Prespecified Third Interim Analysis of the Darolutamide Observational (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): North American (NAm) Subgroup Analysis
Presented By: Christopher Pieczonka, MD
|
|
|
|
|
|
|
| MP38: Kidney Cancer: Epidemiology & Evaluation/Staging/Surveillance IV - 9:30 AM - 11:30 AM
|
|
|
|
|
|
|
Active Surveillance for Clinical Stage T1b Renal Masses in a Large Statewide Collaborative
Presented By: Banna Hussain, MD
|
|
|
|
|
